ITCI — Intra-Cellular Therapies Cashflow Statement
0.000.00%
Last trade - 00:00
- $7.64bn
- $7.14bn
- $464.37m
- 61
- 13
- 66
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -148 | -227 | -284 | -256 | -140 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 19.9 | 23.7 | 30.4 | 43.5 | 44.5 |
Other Non-Cash Items | |||||
Changes in Working Capital | -0.854 | -27.5 | -6.35 | -58.1 | -29.6 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -128 | -230 | -260 | -270 | -124 |
Capital Expenditures | -0.7 | -0.267 | -0.326 | -0.778 | -0.269 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 178 | -480 | 281 | -128 | 106 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 177 | -480 | 280 | -128 | 106 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 3.24 | 664 | 11.5 | 455 | 17.8 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 52.7 | -46.2 | 32.3 | 56.6 | -0.848 |